LQ 036
Alternative Names: LQ-036Latest Information Update: 10 Apr 2025
At a glance
- Originator Shanghai Novamab Biopharmaceuticals
- Class Antiasthmatics; Monoclonal antibodies; Single-domain antibodies
- Mechanism of Action Interleukin 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Asthma
- Phase I Chronic obstructive pulmonary disease
Most Recent Events
- 10 Apr 2025 LQ 036 is still in phase I trials for Asthma in Australia (IV, Infusion) (Inhalation) (Shanghai Novamab Biopharmaceuticals pipeline, April 2025)
- 10 Apr 2025 Phase-I clinical trials in Chronic obstructive pulmonary disease in China (Inhalation), before April 2025 (Shanghai Novamab Biopharmaceuticals pipeline, April 2025)
- 10 Apr 2025 Shanghai Novamab Biopharmaceuticals plans to submit an IND application for Chronic obstructive pulmonary disease (Shanghai Novamab Biopharmaceuticals pipeline, April 2025)